Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
acquired by Bain Capital and Cinven in 2017
|
| gptkbp:CEO |
Peter Goldschmidt
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:founded |
1895
cooperative of pharmacists |
| gptkbp:headquarters_location |
gptkb:Bad_Vilbel
|
| gptkbp:industry |
pharmaceutical industry
|
| gptkbp:ISIN |
DE0007251803
|
| gptkbp:legalForm |
gptkb:company
|
| gptkbp:listedOn |
gptkb:Prime_Standard
|
| gptkbp:market |
gptkb:Asia
gptkb:Europe gptkb:Latin_America gptkb:Middle_East |
| gptkbp:notableProduct |
Aqualibra
Ferro Sanol Grippostad Ladival Mobilat |
| gptkbp:numberOfEmployees |
over 12,000
|
| gptkbp:parentOrganization |
gptkb:Cinven
gptkb:Bain_Capital |
| gptkbp:products |
generic drugs
over-the-counter drugs |
| gptkbp:revenue |
3.25 billion EUR (2022)
|
| gptkbp:stockExchange |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:stockSymbol |
SAZ
|
| gptkbp:website |
https://www.stada.com/
|
| gptkbp:bfsParent |
gptkb:Cinven
gptkb:Markus_Pinger |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Stada Arzneimittel
|